Does RISANKIZUMAB-RZAA Cause Neoplasm recurrence? 5 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Neoplasm recurrence have been filed in association with RISANKIZUMAB-RZAA. This represents 0.0% of all adverse event reports for RISANKIZUMAB-RZAA.
5
Reports of Neoplasm recurrence with RISANKIZUMAB-RZAA
0.0%
of all RISANKIZUMAB-RZAA reports
0
Deaths
0
Hospitalizations
How Dangerous Is Neoplasm recurrence From RISANKIZUMAB-RZAA?
Of the 5 reports.
Is Neoplasm recurrence Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RISANKIZUMAB-RZAA. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does RISANKIZUMAB-RZAA Cause?
Psoriasis (6,896)
Drug ineffective (2,885)
Pain (2,584)
Fatigue (2,483)
Arthralgia (2,419)
Pruritus (2,311)
Covid-19 (2,145)
Death (1,700)
Fall (1,666)
Surgery (1,662)
What Other Drugs Cause Neoplasm recurrence?
CYCLOPHOSPHAMIDE (293)
PALBOCICLIB (248)
DOXORUBICIN (240)
VINCRISTINE (239)
CYTARABINE (223)
METHOTREXATE (198)
CARBOPLATIN (170)
RITUXIMAB (163)
ETOPOSIDE (156)
PREDNISONE (144)
Which RISANKIZUMAB-RZAA Alternatives Have Lower Neoplasm recurrence Risk?
RISANKIZUMAB-RZAA vs RISDIPLAM
RISANKIZUMAB-RZAA vs RISEDRONATE
RISANKIZUMAB-RZAA vs RISEDRONIC ACID
RISANKIZUMAB-RZAA vs RISPERDAL
RISANKIZUMAB-RZAA vs RISPERDAL CONSTA